Evidence map›Paper›PMID 21208901›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2011

Molecular targeting of neural cancer stem cells: TTAGGG, you're it!

Anita B Hjelmeland, Jeremy N Rich

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Anita B HjelmelandDepartment of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
Jeremy N Rich
Cleveland Clinic Lerner College of Medicine · US

Funding

Targeting Brain Tumor Stem Cells Through Novel Therapeutic CombinationsR01CA154130 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI RICH, JEREMY N · 2010 to 2014
$1.9M
Stem Cell-Like Glioma Cells in AngiogenesisR01CA129958 · NCI · DUKE UNIVERSITY · PI RICH, JEREMY N · 2008 to 2012
$1.6M
TGFbeta-PTEN Interactions in Glioma Biology & TherapyR01CA116659 · NCI · DUKE UNIVERSITY · PI RICH, JEREMY N · 2006 to 2010
$1.4M
A20 Promotes Glioma Stem Cell Mediated TumorigenesisR01CA151522 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HJELMELAND, ANITA BORTON · 2010 to 2014
$1.2M
Molecular Mechanisms of SPARC Mediated Glioma InvasionR01NS054276 · NINDS · DUKE UNIVERSITY · PI RICH, JEREMY N · 2006 to 2010
$1.2M
NCI NIH HHS R01 CA116659NCI NIH HHS R01 CA129958NCI NIH HHS R01 CA151522NCI NIH HHS R01 CA154130NINDS NIH HHS R01 NS054276
6 · The paper itself

Abstract

Telomerase is an important mechanism by which cancers escape replicative senescence. In neural tumors, cancer stem cells express telomerase, suggesting that this may explain their preferential tumorigenesis. Oligonucleotide telomerase targeting selectively disrupts cancer stem cell growth through the induction of differentiation, adding to the armamentarium of anticancer stem cell therapies.

Indexed as

AnimalsGliomaHumansNeoplastic Stem CellsNeural Stem CellsNeuroblastomaTelomeraseTelomereTelomerase

Identifiers

PMID21208901
PMCPMC3099413
OpenAlexW2112296346

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.